Related Experiment Video
Updated: Jan 23, 2026
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
Published on: April 3, 2021
Eltrombopag Therapy in Children With Rare Disorders Associated With Thrombocytopenia
Jowita Frączkiewicz1, Dorota Sęga-Pondel, Bernarda Kazanowska
1Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland.
Insights
Eltrombopag (ELT) effectively treats rare pediatric blood disorders by increasing platelet counts. However, treatment response varies based on the underlying condition, with some patients experiencing side effects.
Area of Science:
- Hematology
- Pediatric Hematology
- Pharmacology
Background:
- Eltrombopag (ELT), a thrombopoietin receptor activator, is recognized for its efficacy in chronic immune thrombocytopenia.
- This study investigates ELT's therapeutic outcomes in pediatric patients with rare hematologic disorders.
Observation:
- Four children with Pearson syndrome, DiGeorge syndrome, posttransplant poor graft function (PGF), and Wiskott-Aldrich syndrome received ELT therapy.
- Tolerance was generally good, except for one patient with Pearson syndrome who experienced cataract exacerbation.
- One child developed thromboembolic events despite normalized platelet counts.
Findings:
- Patients with DiGeorge syndrome and PGF achieved independence from platelet transfusions within 4 weeks.
- Successful discontinuation of ELT was observed in one patient, maintaining normal complete blood count (CBC) values.
- Increased neutrophil counts were noted in two patients, with a positive correlation between neutrophil and platelet counts in the PGF patient.
Implications:
- Eltrombopag demonstrates efficacy in treating rare pediatric hematologic disorders, but response patterns are disease-specific.
- Underlying constitutional hematopoiesis defects may impact treatment success.
- ELT offers a promising therapeutic option for specific pediatric hematologic conditions, warranting further investigation into response predictors.
Abstract:
Eltrombopag (ELT) is a thrombopoietin receptor activator that has shown efficacy in chronic immune thrombocytopenia. We report the outcome of ELT therapy in 4 children who were treated for rare hematologic disorders, including Pearson syndrome, DiGeorge syndrome, posttransplant allogeneic poor graft function (PGF), and Wiskott-Aldrich syndrome. The ELT tolerance in the analyzed group was good, with the exception of the child with Pearson syndrome, who experienced an exacerbation of cataracts and had to discontinue treatment. Thromboembolic events were observed in one child, who continued ELT therapy despite achieving normalized platelet counts. Independence from PLT transfusions was observed at the 4-week timepoint of therapy in patients with DiGeorge syndrome and PGF who responded to ELT. Discontinuation of therapy was successful in one child, who sustained the normal CBC values afterward. In 2 patients, an increase in neutrophil counts was observed during ELT therapy without additional intervention, and a positive correlation between neutrophil and platelet values during ELT therapy was observed in the child with PGF. ELT is effective in rare pediatric disorders, but response patterns are determined by the underlying disease. ELT shows promising results in patients, but constitutional hematopoiesis defects reduce the chances of a response.
Related Concept Videos
02:18Intrinsically Disordered Proteins
00:59Gene Therapy
01:30Other Disorders of Digestive System
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...